Rituximab is a Medicine belongs to Antineoplastic group whose information about Brand can be referenced from   Book : Martindale    Page : 848   Edition : 37  

  ►   Brandname : rituxan, Mab Thera
  ►  Strength : Injection with 10 mg/ml. 

Reference of this Medicine for its Strength can be taken from   Book : Basic & Clinical pharmacology    Page : 656   Edition : 12  
A Route of administration in pharmacology and toxicology is the path by which a drug, fluid, poison, or other substance is taken into the body. Routes of administration are generally classified by the location at which the substance is applied. Common examples include oral and intravenous administration.

  ►  Route of administration : IV
Reference :-   Book : Martindale    Page : 845   Edition : 37  

Dosing of Medicine differ in Adult & Pediatrics ↓

Adult Dose

S.No Ailment   Route   Dose Min   Dose Max   Unit   Dosage Form   Frequency   Additional Info
1 Refactory or replased folicular lymphoma IV 357 mg/m2 Injection Dose: once weekly for 4 doses; in the USA 8 doses may be given. Patients in either country may be re-treated after relapse for a further 4 doses. When given with combination chemotherapy such as CVP (for follicular lymphoma) or CHOP (for diffuse large B-cell lymphoma), rituximab 375 mg/m2is given on day 1 of the chemotherapy cycle, after the corticosteroid component of the regimen, for a total of 8 cycles. In patients previously treated with 6 to 8 cycles of CVP chemotherapy and who have not progressed, rituximab 375 mg/m2 may be given once weekly for 4 doses, repeated every 6 months, for up to 16 doses. For maintenance treatment in those who have responded to induction chemotherapy, rituximab 375 mg/m2 is given once every 3 months until disease progression or for a maximum period of 2 years.
2 Chronic lymphocytic leukaemia IV 375 mg/m2 Injection Dose: Dose: Given on the day before chemotherapy in cycle 1, followed by 500 mg/m2 given on day 1 of each subsequent cycle, for up to 6 cycles in total; chemotherapy is given after the rituximab infusion. Prophylactic hydration and allopurinol or rasburicase is recommended, starting 48 hours before rituximab, to reduce the risk of tumor lysis syndrome; in some countries, those with high lymphocyte counts are given intravenous corticosteroids before rituximab to reduce the incidence and severity of infusion reactions.
3 Rheumatoid arthiritis IV 1 gm Injection Dose: the infusions are separated by 2 weeks. It is given with methotrexate, and corticosteroids are recommended before each infusion to reduce the incidence and severity of infusion reactions.

Ref :-  Book : Martindale    Page : 846   Edition : 37  



Pediatric Dose

S.No Ailment   Age Min   Age Max   Weight ( Kg ) Route   Dose Min   Dose Max   Unit   Dosage Form   Frequency  Additional Info  
1 Auto-immune haemolytic anaemia, idiopathic thrombocytopenic purpura and post-transplantation lymphoproliferative disease, as well as rheumatoid arthritis, and SLE IV 375 mg/m2 Injection

Ref :- Book : Martindale    Page : 846   Edition : 37  
►  Side Effect : Cytokine release syndrome, Fever, Chills, Rigors, pruritus, Urticaria, Rashes, Dyspnoea, Bronchospasm, Angioedema, Transient hypotension, Flushing, Myocardial infarction, Ventricular fibrillation, Cardiogenic shock, Asthenia, Headache, Rhinitis, Hypertension, Tumour lysis syndrome, Acute renal failure, Acute respiratory failure, Death, Hypersensitivity reactions, Stevens-Johnson syndrome, Toxic epidermal necrolysis, Lymphopenia, leucopenia, Neutropenia, Thrombocytopenia, Anaemia, Exacerbation of heart failure, Angina pectoris, Arrhythmias, Tachycardia, Gastrointestinal disturbances, Abdominal pain, Bowel obstruction, Perforation
Ref :-   Book : Martindale    Page : 845   Edition : 37.  

►  Drug Interaction : Drug interaction of Rituximab is with Statins,  NA

  ►    Mechanism of Drug Drug Interaction :  Statins significantly decreased rituximab ctytotoxicity.
Ref :-   Book : Martindale    Page : 846   Edition : 37.  


►  Contraindication : Patients with an extensive tumour burden, pulmonary tumour infiltration or pulmonary insufficiency may be at increased risk of severe reactions and should be treated with caution and possibly a decreased initial infusion rate., Use of rituximab is associated with an increase risk of progressive multifocal leukoencephalopathy (PML), and fatilities have been reported., In most cases patients had multiple risk factors, including long-term treatment with combination chemotherapy or immunosuppression, or were undergoing haemopoietic stem cell transplantation., Patients at high risk of HBV infection should be screened before starting rituximab therapy and carriers should be monitored for signs of active infection or hepatitis during and for several months after therapy. Rituximab should be stopped if viral hepatitis develops. Other serious infections, which may be fatal, can occur with rituximab. Cases of progressive multifocal leukoencephalopathy, some fatal, have been reported with rituximab.
Ref :-   Book : Martindale    Page : 845   Edition : 37.  
  ►  Mechanism of Action :   Rituximab is a chimeric monoclonal antibody biologic agent that targets CD20 B lymphocytes. This depletion takes place through cell-mediated and complement-dependent cytotoxicity and stimulation of cell apoptosis. Depletion of B lymphocytes reduces inflammation by decreasing the presentation of antigens to T lymphocytes and inhibiting the secretion of proinflammatory cytokines. Rituximab rapidly depletes peripheral B cells, although this depletion correlates neither with efficacy nor with toxicity.
Ref :-   Book : Basic & Clinical pharmacology    Page : 646   Edition : 12.  

Pathway of DIETARY Product


​   ► Act.Comp / Nutrient / Food / Herb as follows :- Cancer tree with Another pathway.  

  ►  Pathway with its reference as follows :-
  • Camptotecin have anticancer effect --- (Kokate, C.K. and A.p. Purohit. Pharmacognosy. Nirali prakashan: Chennai, 2013. Print. )

  •   ►  URL --
  • http://freepharmadownloads.blogspot.com/2013/02/pharmacognosy-ckkokate-free-download.html .

  • DIETARY Substance Interactions


    ​   ► This Medicine interact with :- NA



    ContraIndication DIETARY Substance


    ​   ► This Medicine contraindicate with :- NA

    ►   Route of Elimination :   NA

    ►    Plasma Half-life :   Min value :-   ~22 days,    Max value :-   NA
    Ref :-   Book : Goodman    Page : 1746   Edition : 12.  

    ►    Peak Plasma Concentration :   Min value :-   NA    Max value :-   NA